Welcome to this special edition of Neurology News Network. I'm Marco Meglio.
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in people with multiple sclerosis (MS) was associated with significantly greater physical activity and improvements across several patient-reported symptom domains, according to new data presented at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in Charlotte, North Carolina. Researchers assessed self-reported moderate-to-vigorous physical activity, as well as SymptoMScreen PRO scores spanning 13 neurologic symptom domains. Physical activity increased substantially after initiation of GLP-1 therapy, rising from 52.3 minutes per week at baseline to 115.7 minutes per week following treatment, representing a mean increase of 65.8 minutes weekly (95% CI, 48.5-83.0; P <.001).
Dyne Therapeutics has submitted a biologics license application (BLA) to the FDA seeking accelerated approval of zeleciment rostudirsen (z-rostudirsen; formerly DYNE-251) for patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping, marking a major regulatory milestone for the investigational exon-skipping therapy. The submission is supported by findings from the phase 1/2 DELIVER trial (NCT05524883), in which treatment with z-rostudirsen led to statistically significant increases in dystrophin production alongside improvements across multiple functional endpoints and a favorable safety profile. Dyne has requested Priority Review, which could shorten the FDA review timeline from 10 months to 6 months if granted. The company continues to anticipate a potential U.S. launch in the first quarter of 2027.
A newly published single-center observational study in China showed that ofatumumab (Kesimpta; Novartis) treatment was associated with significant reductions in annualized relapse rate (ARR) compared with off-label rituximab in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). In addition to demonstrating a favorable safety profile, these findings suggest that ofatumumab may be associated with greater relapse reduction compared with rituximab in patients with MOGAD. Before initiating treatment, patients who received ofatumumab (n = 22) had a median of 2 relapses and an ARR of 1.30 (95% CI, 0.74-2.29). Over a median treatment duration of 19.5 months, 4 patients (18.18%) experienced relapse, with ARR decreasing to 0.12 (95% CI, 0.04-0.35), corresponding to an incidence rate ratio (IRR) of 10.86 (95% CI, 3.22-36.70; P <.001). In the rituximab group (n = 21), patients had a median of 2 relapses before treatment initiation and an ARR of 1.34 (95% CI, 0.73-2.48).
For more direct access to expert insight, head to NeurologyLive.com. This has been Neurology News Network. Thanks for watching.
